The growth-inhibitory effects of
gemcitabine for PANC-1 and MIA-PaCa2 were determined.
When researchers at King's College Hospital and Southampton University combined the American chokeberry (above) with
gemcitabine, a chemotherapy drug used for pancreatic cancer, they discovered it increased the effectiveness of the chemotherapy.
This study reports the use of intravesical
gemcitabine in managing patients with high-risk bladder cancer, refractory to Bacillus Calmette-Guerin (BCG).
This study has enrolled 200 patients with metastatic pancreatic cancer who were not considered suitable for combination chemotherapy and is designed to evaluate the efficacy and safety of Acelarin monotherapy compared to
gemcitabine, with further exploration of patient sub-groups that may derive additional benefit from Acelarin.
Radiation and the chemotherapy drug
gemcitabine, which are the standard treatment for pancreatic cancer, both work by causing damage to DNA.
Gemcitabine HCL has grabbed eyeballs of stakeholders alike.
In the human clinical trial, they evaluated the safety and potential efficacy of IVC combined with radiation treatment and
gemcitabine chemotherapy for patients with locally advanced pancreatic cancer compared to matched historical controls who received
gemcitabine and radiation but not IVC.
These new preclinical results show synergistic antitumour effects in vivo using CAN04, also in combination with carboplatin or oxaliplatin, as well as CAN04 combined with the cisplatin and
gemcitabine doublet.
Gemcitabine is a deoxycytidine analog that exhibits anticancer activity against various solid tumors such as pancreatic cancer, lung cancer and prostate cancer (28,29).